Departamento de Infectologia Instituto Nacional de Cancerologia Av. San Fernando 22, Col. Sección XVI Tlalpan, Mexico City, Mexico
Med Oral Patol Oral Cir Bucal. 2022 Mar 1;27(2):e150-e158. doi: 10.4317/medoral.25092.
Survival of patients with oral squamous cell carcinoma (OSCC) is generally low, with the likelihood of locoregional recurrence or disease progression (LR/DP). Knowledge of prognostic factors for survival is key to achieving an understanding and increased survival. The present study aimed to identify prognostic factors for patients with OSCC, especially the presence of DNA from human papillomavirus (HPV).
Retrospective cohort study including 119 patients with OSCC treated at the National Cancer Institute in Mexico City (2009-2013). Clinical information was obtained from patient records including LR/DP. Formalin-fixed, paraffin-embedded tissues were obtained and used for detecting DNA from different types of HPV. Potential prognostic factors for Overall Survival (OS) were analyzed using the Cox proportional hazards model.
After model adjustment, factors associated with longer OS were a pre-treatment platelet count above 400,000/mm3 (HR=0.09, p=0.026) and response to primary treatment (HR=0.26, p=0.001). HPV DNA was present in 23 (19.3%) of the patients and importantly, type 16 found in 19 of them. Although survival of HPV-positive patients was longer, difference was not significant. However, among patients with LR/DP, HPV positivity was significantly associated with increased survival (HR=0.23, p=0.034). Importantly, survival was significantly different for HPV-positive patients with LR/DP > 6 months (HR=0.20, p=0.002), had higher absolute lymphocyte count at start of treatment (HR=0.50, p=0.028) or had local rescue treatment (HR=0.24, p=0.019).
Although HPV positivity was not associated with a longer OS of OSCC patients, a better prognosis was significantly associated with HPV positivity and recurring or progressing disease, particularly with HPV type 16.
口腔鳞状细胞癌(OSCC)患者的生存率一般较低,存在局部区域复发或疾病进展(LR/DP)的可能性。了解生存的预后因素是理解和提高生存率的关键。本研究旨在确定 OSCC 患者的预后因素,特别是存在人乳头瘤病毒(HPV)的 DNA。
这是一项回顾性队列研究,纳入了 119 名在墨西哥城国家癌症研究所接受治疗的 OSCC 患者(2009-2013 年)。临床信息从患者记录中获得,包括 LR/DP。获得福尔马林固定、石蜡包埋的组织,用于检测不同类型 HPV 的 DNA。使用 Cox 比例风险模型分析总生存(OS)的潜在预后因素。
经过模型调整,与较长 OS 相关的因素包括治疗前血小板计数高于 400,000/mm3(HR=0.09,p=0.026)和对初始治疗的反应(HR=0.26,p=0.001)。23 名(19.3%)患者的 HPV DNA 呈阳性,其中 19 名患者存在 16 型 HPV。尽管 HPV 阳性患者的生存率较长,但差异无统计学意义。然而,在有 LR/DP 的患者中,HPV 阳性与生存率增加显著相关(HR=0.23,p=0.034)。重要的是,LR/DP > 6 个月的 HPV 阳性患者的生存率差异有统计学意义(HR=0.20,p=0.002),治疗开始时绝对淋巴细胞计数较高(HR=0.50,p=0.028)或接受局部挽救治疗(HR=0.24,p=0.019)。
尽管 HPV 阳性与 OSCC 患者的 OS 无明显相关性,但 HPV 阳性与复发或进展性疾病显著相关,预后较好,尤其是与 HPV 16 型相关。